[HTML][HTML] Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease
G Marucci, M Buccioni, D Dal Ben, C Lambertucci… - …, 2021 - Elsevier
Abstract Alzheimer's disease (AD), the most common cause of adult-onset dementia is
characterized by a progressive decline of cognitive functions accompanied by behavioral …
characterized by a progressive decline of cognitive functions accompanied by behavioral …
Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies
AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …
aging population worldwide. The enormous challenge which AD possesses to global …
Inhibitory potential of nitrogen, oxygen and sulfur containing heterocyclic scaffolds against acetylcholinesterase and butyrylcholinesterase
Heterocycles are the key structures in organic chemistry owing to their immense applications
in the biological, chemical, and pharmaceutical fields. Heterocyclic compounds perform …
in the biological, chemical, and pharmaceutical fields. Heterocyclic compounds perform …
The neuroprotective potentiality of flavonoids on Alzheimer's disease
Alzheimer's disease (AD), due to its spread, has become a global health priority, and is
characterized by senile dementia and progressive disability. The main cause of AD and …
characterized by senile dementia and progressive disability. The main cause of AD and …
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease
A Haake, K Nguyen, L Friedman… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's …
Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition
with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) …
with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) …
Current treatment options for Alzheimer's disease and Parkinson's disease dementia
J YY Szeto, S JG Lewis - Current neuropharmacology, 2016 - ingentaconnect.com
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common
neurodegenerative disorders encountered in clinical practice. Whilst dementia has long …
neurodegenerative disorders encountered in clinical practice. Whilst dementia has long …
A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease
Alzheimer's disease (AD) is an age-related multifactorial neurodegenerative disorder
characterized by severe central cholinergic neuronal loss, gradually contributing to cognitive …
characterized by severe central cholinergic neuronal loss, gradually contributing to cognitive …
Biogenic synthesis of gold nanoparticles from Terminalia arjuna bark extract: assessment of safety aspects and neuroprotective potential via antioxidant …
The development of neuroprotective drugs through eco-friendly production routes is a major
challenge for current pharmacology. The present study was carried out to synthesize gold …
challenge for current pharmacology. The present study was carried out to synthesize gold …
Multitarget drug design strategy: quinone–tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects
E Nepovimova, E Uliassi, J Korabecny… - Journal of medicinal …, 2014 - ACS Publications
We report the identification of multitarget anti-Alzheimer compounds designed by combining
a naphthoquinone function and a tacrine fragment. In vitro, 15 compounds displayed …
a naphthoquinone function and a tacrine fragment. In vitro, 15 compounds displayed …